Bicara Therapeutics Inc. Income Statement
BCAX / Health Care|2 years of annual SEC 10-K data (FY2023-FY2024)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 2 fiscal years. All figures from audited SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 11.58 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 |
|---|---|---|
| SG&A Expense | $18.8M | $9.3M |
| R&D Expense | $63.6M | $30.6M |
| Operating Income | -$82.4M | -$39.9M |
| Income Tax | $180.0K | $5.0K |
| Net Income | -$68.0M | -$52.0M |
| EPS (Basic) | -$4.05 | -$89.61 |
| EPS (Diluted) | -$4.05 | -$89.61 |
| Shares Outstanding | 16.8B | 580.1M |